Pegylated interferon lambda

A new drug quashes all coronavirus variants. But regulatory hurdles and a lack of funding make it unlikely to reach the U.S. market anytime soon.

So starts the NYT article.  Have we learned nothing?  As for the drug itself, the news is good:

…a new class of variant-proof treatments could help restock the country’s armory. Scientists on Wednesday reported in The New England Journal of Medicine that a single injection of a so-called interferon drug slashed by half a Covid patient’s odds of being hospitalized.

The results, demonstrated in a clinical trial of nearly 2,000 patients, rivaled those achieved by Paxlovid. And the interferon shots hold even bigger promise, scientists said. By fortifying the body’s own mechanisms for quashing an invading virus, they can potentially help defend against not only Covid, but also the flu and other viruses with the potential to kindle future pandemics.

We will see if this has the opportunity to progress.  Fast Grants, working in conjunction with Rainwater Foundation, was a key early funder here.

Oh, and do note this:

As it stands, Eiger executives said that they might seek authorization for the interferon shot outside of the United States. China, for example, has been looking for new treatment options.

And here is an Eric Topol thread on the results.


Comments for this post are closed